Amphotericin B in neonates: Deoxycholate or lipid formulation as first-line therapy - Is there a 'right' choice?

Current Opinion in Infectious Diseases

Volumn 24, Issue 2, 2011, Pages 163-171

  Turkova, Anna ^a   Roilides, Emmanuel ^a   Sharland, Mike ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

amphotericin; antifungal; neonatal fungal infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FLUCYTOSINE; MICAFUNGIN; POTASSIUM;

ABNORMAL LABORATORY RESULT; ANEMIA; BACTERIAL ARTHRITIS; BONE MARROW SUPPRESSION; CANDIDA ALBICANS; CANDIDA MENINGITIS; CANDIDA PARAPSILOSIS; CANDIDEMIA; CENTRAL NERVOUS SYSTEM INFECTION; CHILL; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; ELECTROLYTE DISTURBANCE; ENDOCARDITIS; ENDOPHTHALMITIS; ENZYME BLOOD LEVEL; EYE DISEASE; FEVER; FUNGEMIA; FUNGUS BALL; GLOMERULUS FILTRATION RATE; HUMAN; HYPOKALEMIA; INVASIVE CANDIDIASIS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE ACIDOSIS; LIVER TOXICITY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEWBORN; NEWBORN MORTALITY; NONHUMAN; OLIGURIA; OSTEOARTHRITIS; OSTEOMYELITIS; POTASSIUM BLOOD LEVEL; PREMATURITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SODIUM INTAKE; SYSTEMIC MYCOSIS; THROMBOCYTOPENIA; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; VERY LOW BIRTH WEIGHT;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MYCOSES; TREATMENT OUTCOME;

EID: 79952193176     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328343614e     Document Type: Review

References (66)

1. Blyth CC, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010:CD006343. doi:10.1002/14651858.
2. Clerihew L, McGuire W. Systemic antifungal drugs for invasive fungal infection in preterm infants. Cochrane Database Syst Rev 2004:CD003953. doi:10.1002/14651858.
3. Driessen M, Ellis JB, Cooper PA, et al. Fluconazole versus amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996; 15:1107-1112. (Pubitemid 27014703)
4. Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129:63-71. (Pubitemid 26277248)
5. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17:504-508. (Pubitemid 28287618)
6. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660-1666. (Pubitemid 33126821)
7. Clerihew L, Lamagni TL, Brocklehurst P, et al. Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed 2006; 91:F188-F192. (Pubitemid 43667617)
8. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006; 117:84-92. (Pubitemid 46050523)
9. Manzoni P, Stolfi I, Pugni L, et al. A multicentre, randomized trial of prophylactic fluconazole in preterm neonates. N Engl JMed 2007; 356:2483-2495. (Pubitemid 46919774)
10. Makhoul IR, Sujov P, Smolkin T, et al. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics 2002; 109:34-39. (Pubitemid 34049424)
11. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285-291. (Pubitemid 34833012)
12. Benjamin DK Jr, Poole C, Steibach WJ, et al. Neonatal candidemia and end organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003; 112:634-640. (Pubitemid 37082118)
13. Johnson DE, Thompson TR, Green TP, Ferrieri P. Systemic candidiasis in very low-birth-weight infants (<1500 grams). Pediatrics 1984; 73:138-143. (Pubitemid 14188493)
14. Chapman RL. Prevention and treatment of Candida infections in neonates. Semin Perinatol 2007; 31:39-46. (Pubitemid 46273662)
15. Bliss JM, Wellington M, Gigliotti F. Antifungal pharmacotherapy for neonatal candidiasis. Semin Perinatol 2003; 27:365-374. (Pubitemid 37363189)
16. Steinbach WJ, Perfect JR. Antifungal agents. In: Yaffe SJ, Aranda JV, editors. Neonatal and pediatric pharmacology: therapeutic principles in practice, 3rd ed. Philadelphia: Lippincot Williams & Wilkins; 2005. pp. 459-462.
17. Fungizone SPC (date of revision 28/07/2010). The electronic Medicines Compendium (eMC). http://www.medicines.org.uk (accessed 7 August 2010).
18. Starke JR, Mason EO, Kramer WG Jr, Kaplan SL. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 1987; 155:766-774. (Pubitemid 17053000)
19. Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990; 116:791.
20. Higuchi R, Kusumoto S, Ban H, et al. Increased level/dose ratio of amphotericin-B in premature infants with renal failure. Acta Paediatr Jpn 1993; 35:238-242. (Pubitemid 23162557)
21. Juster-Reicher A, Flidel-Rimon O, Amitay M, et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003; 22:603-607. (Pubitemid 37363539)
22. Moreira M. Controversies about the management of invasive fungal infections in very low birth weight infants. J Pediatr (Rio J) 2005; 81:S52-S58. (Pubitemid 41702741)
23. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535.
24. Coukell AJ, Brogden RN. Liposomal amphotericin B: therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 1998; 55:585-612. (Pubitemid 28162079)
25. Frattarelli DA, Reed MD, Giacoia GP, Aranda JV. Antifungals in systemic neonatal candidiasis. Drugs 2004; 64:949-968. (Pubitemid 38608474)
26. Swenson CE, Perkins WR, Roberts P, et al. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother 1998; 42:767-771.
27. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and preclinical experience. J Antimicrob Chemother 2002; 49:S21-S30.
28. Wurthwein G, Groll AH, Hempel G, et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 2005; 49:5092-5098. (Pubitemid 41778925)
29. AmBisome SPC (date of revision 20/07/2010). The electronic Medicines Compendium (eMC). http://www.medicines.org.uk (accessed 7 August 2010).
30. Biyikli NK, Tugtepe H, Akpmar I, et al. The longest use of liposomal amphotericin B and 5-fluorocytosine. Pediatr Nephrol 2004; 19:801-804. (Pubitemid 38931167)
31. Evdoridou J, Roilides E, Bibashi E, Kremenopoulos G. Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Infection 1997; 25:112-116. (Pubitemid 27145849)
32. Kotwani RN, Gokhale PC, Bodhe PV, et al. A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates. Int J Pharm 2002; 238:11-15. (Pubitemid 34457871)
33. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity. Pediatrics 1984; 73:153.
34. Faix RG. Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement. J Pediatr 1984; 105:616-622. (Pubitemid 14003580)
35. Loke HL, Verber I, Szymonowicz W, Yu VY. Systemic candidiasis and pneumonia in preterm infants. Aust Paediatr J 1988; 24:138-142.
36. Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990; 9:51-56.
37. Leibovitz E, Juster-Reicher A, Amitai M, et al. Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin Infect Dis 1992; 14:485-491.
38. Glick C, Graves GR, Feldman S. Neonatal fungemia and amphotericin B. South Med J 1993; 86:1368-1371. (Pubitemid 24007167)
39. Kingo AR, Smyth JA, Waisman D. Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr Infect Dis J 1997; 16:1002-1003. (Pubitemid 27452322)
40. Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000; 31:458-463.
41. Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 2003; 52:663-667. (Pubitemid 37258429)
42. Jeon GW, Koo SH, Lee JH, et al. A comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants. Yonsei Med J 2007; 48:619-626. (Pubitemid 47496723)
43. Turcu R, Patterson MJ, Omar S. Influence of sodium intake on amphotericin Binduced nephrotoxicity among extremely premature infants. Pediatr Nephrol 2009; 24:497-505.
44. Scarcella A, Pasquariello M, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998; 17:146-148. (Pubitemid 28096014)
45. Weitkamp JH, Poets CF, Sievers R, et al. Candida infection in very low birthweight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998; 26:11-15. (Pubitemid 28062153)
46. Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000; 28:223-226. (Pubitemid 30601420)
47. López Sastre JB, Coto Cotallo GD, Fernández Colomer B. Neonatal invasive candidiasis: a prospective multicentre study of 118 cases. Am J Perinatol 2003; 20:153-163. (Pubitemid 36682311)
48. Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed 2001; 84:F131-F133. (Pubitemid 32250858)
49. Chapman R, Faix R. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J 2000; 19:822-827.
50. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27:820-826.
51. Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 2004; 26:421-426. (Pubitemid 39025253)
52. Turner RB, Donowitz LG, Hendley JO. Consequences of candidemia for pediatric patients. Am J Dis Child 1985; 139:178-180. (Pubitemid 15153783)
53. Le J, Adler-Shohet FC, Nguen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J 2009; 28:1061-1063.
54. Holler B, Omar SA, Farid MD, Patterson MJ. Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants. Pediatrics 2004; 113:e608-e616.
55. Sabra R, Robert AB. Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats. Antimirob Agents Chemother 1991; 35:2509-2514.
56. Anderson CM. Sodium chloride treatment of amphotericin B nephrotoxicity: standard of care? West J Med 1995; 162:313-317.
57. Fernando AM, Heath PT, Menson EN. Antimicrobial policies in the neonatal units of the United Kingdom and Republic of Ireland. J Antimicrob Chemother 2008; 61:743-745. (Pubitemid 351321155)
58. Prasad PA, Coffin SE, Leckerman KH, et al. Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J 2008; 27:1083-1088.
59. Kontou A, Thomaidou A, Groll A et al. Management of invasive fungal infections in neonates and children: responses to a questionnaire to ESPID members. The 28th Annual Meeting of European Society of Pediatric Infectious Diseases (ESPID). Nice, France; 4-8 May 2010.
60. Paediatric Formulary Committee. BNF for children. 2010-2011 ed. London: BMJ Publishing Group, Pharmaceutical Press, and RCPCH Publications; 2010. pp. 370-371.
61. Neonatal formulary: drug use in pregnancy and first year of life. 5th ed. In: Hey E, editor. Oxford: Blackwell Publishing Ltd; 2007. p.40.
62. Allen U, Richardson S, McGuire W, et al. Pediatric antifungal therapy. Part II; neonatal infections. Minerva Pediatr 2010; 62:71-78.
63. Koren G, Lau A, Klein J, et al. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr 1988; 113:559-563.
64. Hope WW, Warn PA, Sharp A, et al. Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. Antimicrob Agents Chemother 2007; 51:3760-3762. (Pubitemid 47519374)
65. Almirante B, Rodriguez D. Antifungal agents in neonates: issues and recommendations. Pediatr Drugs 2007; 9:311-321. (Pubitemid 47557113)
66. Smego RA, Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984; 6:791-801.